Literature: Osimertinib purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 23;38(1):219. [Abstract]
Customer Validation: U87 and U251 cells are treated with AZD9291 (Osimertinib) or CP-358774 for 4, 24 and 48 h. The expression level of p-ERK are assessed using Western blot analysis.
Asterriquinone (ARQ) is an Asterriquinone analog and Grb-2 binding inhibitor that inhibits the binding activity of Grb-2 to tyrosine-phosphorylated EGFR with an IC50 of 8.37 μM, acts as an HIV1 reverse transcriptase inhibitor with a Ki of 2.3 μM, and also inhibits Grb-7 and PLC-γ binding activities.
Clinical Trial
NCT Number
Sponsor
Condition
Start Date
Phase
NCT01502800
University of Texas Southwestern Medical Center|ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Solid Tumors
2011-12-29
PHASE1
NCT00524524
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Advanced Solid Tumors
2007-08
PHASE1
NCT01468922
National Cancer Institute (NCI)
Solid Tumor
2012-01-23
PHASE1
NCT00988741
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Unresectable Hepatocellular Carcinoma
2009-09
PHASE2
NCT01377376
Kyowa Kirin Co., Ltd.
Non-small-cell Lung Cancer
2011-07
PHASE3
NCT02476955
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Solid Tumors|Ovarian Cancer|Endometrial Cancer
2015-06-09
PHASE1
NCT03317366
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)